USE OF ANTIGEN Кі-67 IN BASAL-LIKE BREAST CANCER DIAGNOSTICS IN THE CONDITIONS OF LARGE INDUSTRIAL REGION OF SOUTHEAST OF UKRAINE

Abstract

Introduction. Аlong all molecular genetic types of breast cancer, basal-like tumors account 10–24 %. To carry out more proficient monitoring different biological markers that allow detecting the most aggressive tumors were revealed and applied in practice. One of such markers is Ki-67.

The aim of the study – to learn Ki-67 expression in basal-like breast cancers in the conditions of large industrial region of southeast of Ukraine.

Research Methods. Immunohistological researches were held among patients, living in a large industrial place in south-eastern Ukraine. For all patients (150 persons) with basal-like form of mammary gland and for patients with other molecular-genetic forms (40 persons) of cancer of mammary gland analysed the level of expression (by B. Risberg of et al.) of antigen of Кі-67.

Results and Discussion. The results of immunohistochemical studies of patients with breast cancer were analyzed, in particular, according to the degree of expression of the Ki-67 proliferation marker, depending on the place of residence. A tendency was established to increase the expression of the Ki-67 proliferation marker when evaluating patients living in different areas of Zaporizhzhia (from environmentally friendly to areas that are close to large industrial sites). The Ki-67 proliferation marker was determined in all 150 patients with breast cancer with different expression levels. In a group of patients (40 individuals) with other molecular genetic types of breast cancer, the expression of Ki-67 was detected in 24 (60.0 %) cases; in 16 (40.0 %) cases, expression of the Ki-67 proliferation marker was not determined; a high level of expression of Ki-67 was determined in 2.5 % of patients in this group.

Conclusions. It is set features of motion of basal-like breast cancer from the presence of Ki-67. Frequency of origin of basal-like breast cancer rises on 41–44 % for patients, that live in boroughs of Zaporizhzhia, near to the industrial grounds. These patients look after the increase of expression of marker of proliferative of Ki – 67 on 45 %. Patients with a low level of Ki-67 expression (0–15%) live twice as long as patients with breast cancer with a high level (>50 %) of Ki-67 expression. In patients with breast cancer with low expression of Ki-67 (according to the Risberg classification), overall survival reaches 25 months or more. It was determined that the metastasis of patients with basal-like breast cancer depends on the level of expression of the proliferation marker. At a proliferation marker expression level of 51–100 %, metastasis was detected in 56.80 %. The frequency of relapses in patients with breast cancer is associated with the expression level of the proliferation marker Ki-67. The relapse rate in groups where Ki-67 expression reached 26–50 % and 51–100 % is 7.40 % and 22.22 %, respectively.